SG11201907754RA - Anti-phf-tau antibodies and uses thereof - Google Patents

Anti-phf-tau antibodies and uses thereof

Info

Publication number
SG11201907754RA
SG11201907754RA SG11201907754RA SG11201907754RA SG11201907754RA SG 11201907754R A SG11201907754R A SG 11201907754RA SG 11201907754R A SG11201907754R A SG 11201907754RA SG 11201907754R A SG11201907754R A SG 11201907754RA SG 11201907754R A SG11201907754R A SG 11201907754RA
Authority
SG
Singapore
Prior art keywords
international
antibodies
johnson
rule
ephf
Prior art date
Application number
SG11201907754RA
Inventor
Marc Mercken
Thomas Malia
Marianne Borgers
Kolen Kristof Van
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of SG11201907754RA publication Critical patent/SG11201907754RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7047—Fibrils-Filaments-Plaque formation

Abstract

Comparisonof Recombinant PT to Purified, Hybridoma Derived PT3 . ePHF and Soluble Tau Binding 1.2 0:8 - ----ePHF - R3788 ePHF -hyb PT3 soluble - R3788 - soluble - hyb PT3 .17.4 O 0 0 LC, LX) O 0 LC, C, LV O LC/ CV CO CO CO 0, LO Cv: n mL E O 0.6 0.4 0.2 (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 20 September 2018 (20.09.2018) WIP0 I PCT °Ens °nolo olomonomu Imo oimIE (10) International Publication Number WO 2018/170351 Al (51) International Patent Classification: C07K 16/00 (2006.01) (21) International Application Number: PCT/US2018/022782 (22) International Filing Date: 16 March 2018 (16.03.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/472,214 16 March 2017 (16.03.2017) US (71) Applicant: JANSSEN BIOTECH, INC. [US/US]; 800/850 Ridgeview Drive, Horsham, Pennsylvania 19044 (US). (72) Inventors: MERCKEN, Marc; Turnhoutseweg 30, 2340 Beerse (BE). MALIA, Thomas; 825 N. 29th St., Philadel- phia, Pennsylvania 19130 (US). BORGERS, Marianne; Turnhoutseweg 30, 2340 Beerse (BE). VAN KOLEN, Kristof; Turnhoutseweg 30, 2340 Beerse (BE). (74) Agent: SHIRTZ, Joseph F. et al.; Johnson & Johnson, One Johnson & Johnson Plaza, New Brunswick, New Jer- sey 08933 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (54) Title: ANTI-PHF-TAU ANTIBODIES AND USES THEREOF Fla 1 1-1 11 O 1 -1 (57) : Monoclonal anti-PHF-tau antibodies and antigen-binding fragments thereof are described. Also described are nucleic © acids encoding the antibodies, compositions comprising the antibodies, methods of producing the antibodies and using the antibodies C for treating or preventing conditions such as tauopathies. [Continued on next page] WO 2018/170351 Al MIDEDIMOMOIDEIREEMOMMEHOMIDINEVOIMIE Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(H)) as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
SG11201907754RA 2017-03-16 2018-03-16 Anti-phf-tau antibodies and uses thereof SG11201907754RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762472214P 2017-03-16 2017-03-16
PCT/US2018/022782 WO2018170351A1 (en) 2017-03-16 2018-03-16 Anti-phf-tau antibodies and uses thereof

Publications (1)

Publication Number Publication Date
SG11201907754RA true SG11201907754RA (en) 2019-09-27

Family

ID=63521020

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201907754RA SG11201907754RA (en) 2017-03-16 2018-03-16 Anti-phf-tau antibodies and uses thereof

Country Status (21)

Country Link
US (3) US10766953B2 (en)
EP (1) EP3596119A4 (en)
JP (2) JP7159185B2 (en)
KR (2) KR20230155025A (en)
CN (2) CN110799531B (en)
AR (1) AR111288A1 (en)
AU (1) AU2018234709A1 (en)
BR (3) BR112019019049A2 (en)
CA (1) CA3055598A1 (en)
CL (1) CL2019002566A1 (en)
EA (1) EA201992038A1 (en)
IL (2) IL310464A (en)
JO (1) JOP20180021A1 (en)
MA (1) MA47789A (en)
MX (1) MX2019010922A (en)
PH (1) PH12019501973A1 (en)
SG (1) SG11201907754RA (en)
TW (1) TWI771389B (en)
UY (1) UY37635A (en)
WO (1) WO2018170351A1 (en)
ZA (1) ZA202101318B (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014248515B2 (en) 2013-03-13 2019-03-07 Prothena Biosciences Limited Tau immunotherapy
EP3452507B1 (en) 2016-05-02 2022-10-19 Prothena Biosciences Limited Tau immunotherapy
EA201892417A1 (en) 2016-05-02 2019-05-31 Протена Биосайенсис Лимитед ANTIBODIES RECOGNIZING TAU
WO2018152359A1 (en) 2017-02-17 2018-08-23 Denali Therapeutics Inc. Anti-tau antibodies and methods of use thereof
AU2018263935A1 (en) 2017-05-02 2019-12-19 Prothena Biosciences Limited Antibodies recognizing tau
KR20200058480A (en) 2017-10-16 2020-05-27 에자이 알앤드디 매니지먼트 가부시키가이샤 Anti-tau antibodies and uses thereof
JP2022524588A (en) 2019-03-03 2022-05-09 プロセナ バイオサイエンシーズ リミテッド Tau recognition antibody
KR102633666B1 (en) * 2019-05-31 2024-02-06 일라이 릴리 앤드 캄파니 Compounds and methods for targeting human tau
WO2021024209A1 (en) * 2019-08-06 2021-02-11 Aprinoia Therapeutics Inc. Antibodies that bind to pathological tau species and uses thereof
CN115697393A (en) * 2020-04-08 2023-02-03 詹森生物科技公司 anti-PHF-tau antibodies and uses thereof
IL299822A (en) * 2020-07-14 2023-03-01 Janssen Pharmaceutica Nv Blood-based assay for detecting tauopathy or amyloidogenic disease
IL302386A (en) * 2020-10-26 2023-06-01 Janssen Pharmaceutica Nv Methods of reducing tau in human subjects
TW202231661A (en) * 2020-10-26 2022-08-16 比利時商健生藥品公司 Method of safe administration of anti-tau antibody
JP2024509683A (en) * 2021-02-19 2024-03-05 エーザイ・アール・アンド・ディー・マネジメント株式会社 Anti-PT217 TAU antibody
AU2022242135A1 (en) 2021-03-26 2023-11-09 Janssen Biotech, Inc. Anti-tau antibodies and uses thereof
WO2023092004A1 (en) 2021-11-17 2023-05-25 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
CN117003863A (en) * 2022-04-28 2023-11-07 厦门大学 Antibodies to p-tau 217 and uses thereof
CN116948023B (en) * 2023-09-14 2024-02-09 北京凯祥弘康生物科技有限公司 Tau protein antibodies and uses thereof
CN116948024B (en) * 2023-09-14 2024-02-06 北京凯祥弘康生物科技有限公司 anti-Tau protein capture antibodies

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DE122004000008I1 (en) 1991-06-14 2005-06-09 Genentech Inc Humanized heregulin antibody.
AU662178B2 (en) 1991-10-25 1995-08-24 N.V. Innogenetics S.A. Monoclonal antibodies directed against the microtubule-associated protein tau
US6008024A (en) * 1993-12-21 1999-12-28 Innogenetics, N.V. Monoclonal antibodies specific for PHF-tau, hybridomas secreting them, antigen recognition by these antibodies and their applications
US6121003A (en) 1994-07-29 2000-09-19 Innogentics N.V. Monoclonal antibodies specific for an epitope of phosphorylated tau, and their use
WO2004006955A1 (en) 2001-07-12 2004-01-22 Jefferson Foote Super humanized antibodies
US7657380B2 (en) 2003-12-04 2010-02-02 Xencor, Inc. Methods of generating variant antibodies with increased host string content
CN1780855B (en) 2003-01-24 2011-03-30 应用分子进化公司 Human il-1 beta antagonists
EP1720908A2 (en) 2004-02-17 2006-11-15 Absalus, Inc. Super-humanized antibodies against respiratory syncytial virus
US20070048785A1 (en) 2004-06-09 2007-03-01 Lin Laura L Anti-IL-13 antibodies and complexes
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
JP5406027B2 (en) 2006-08-04 2014-02-05 ノバルティス アーゲー EphB3-specific antibodies and uses thereof
JP2010235447A (en) 2007-07-30 2010-10-21 Igaku Seibutsugaku Kenkyusho:Kk Inhibitory agent for inflammatory cytokine
WO2010045340A1 (en) 2008-10-14 2010-04-22 Centocor Ortho Biotech Inc. Methods of humanizing and affinity-maturing antibodies
CA2742968C (en) * 2008-11-07 2020-06-09 Fabrus Llc Combinatorial antibody libraries and uses thereof
US9968574B2 (en) 2009-05-15 2018-05-15 The University Of Kentucky Research Foundation Treatment of MCI and Alzheimer's disease
CN102596221B (en) 2009-06-10 2019-06-04 纽约大学 The immune targeting of pathological TAU proteins
US8609097B2 (en) 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
US8912355B2 (en) 2009-09-29 2014-12-16 University Of Ottawa Heart Institute Linoleic phospholipids and uses thereof for inhibiting inflammatory and neurodegenerative processes
ES2826883T3 (en) 2009-10-14 2021-05-19 Janssen Biotech Inc Antibody affinity maturation methods
ES2566602T3 (en) 2010-04-09 2016-04-14 Aveo Pharmaceuticals, Inc. Anti-ErbB3 antibodies
WO2012045882A2 (en) 2010-10-07 2012-04-12 Ac Immune S.A. Pharmaceutical composition
EA031698B1 (en) * 2010-10-11 2019-02-28 Байоджен Интернэшнл Нейросайенз Гмбх Human anti-tau antibodies
BR112014015323B1 (en) 2011-12-20 2022-09-27 Janssen Biotech, Inc ANTI-PHF-TAU ANTIBODIES, ITS PRODUCTION METHOD, ISOLATED POLYNUCLEOTIDE ENCODING AN ANTIBODY VH, AND VECTOR

Also Published As

Publication number Publication date
KR102597462B1 (en) 2023-11-03
US20180265575A1 (en) 2018-09-20
EP3596119A4 (en) 2021-01-13
JP2020513804A (en) 2020-05-21
WO2018170351A8 (en) 2019-12-19
MA47789A (en) 2020-01-22
BR122023021947A2 (en) 2024-02-20
ZA202101318B (en) 2023-03-29
US20230047413A1 (en) 2023-02-16
BR112019019049A2 (en) 2020-04-22
US20210179696A1 (en) 2021-06-17
IL310464A (en) 2024-03-01
MX2019010922A (en) 2019-11-08
AR111288A1 (en) 2019-06-26
JP2022191383A (en) 2022-12-27
WO2018170351A1 (en) 2018-09-20
JOP20180021A1 (en) 2019-01-30
CN117209599A (en) 2023-12-12
IL268700B1 (en) 2024-03-01
TW201900682A (en) 2019-01-01
EA201992038A1 (en) 2020-02-06
US11365244B2 (en) 2022-06-21
CN110799531A (en) 2020-02-14
BR122023021958A2 (en) 2024-02-20
CL2019002566A1 (en) 2019-12-27
EP3596119A1 (en) 2020-01-22
TWI771389B (en) 2022-07-21
PH12019501973A1 (en) 2020-06-29
JP7159185B2 (en) 2022-10-24
IL268700A (en) 2019-10-31
KR20230155025A (en) 2023-11-09
CA3055598A1 (en) 2018-09-20
KR20190130133A (en) 2019-11-21
US10766953B2 (en) 2020-09-08
CN110799531B (en) 2023-08-04
AU2018234709A1 (en) 2019-08-29
UY37635A (en) 2018-09-28

Similar Documents

Publication Publication Date Title
SG11201907754RA (en) Anti-phf-tau antibodies and uses thereof
SG11201906297QA (en) Nucleic acids encoding crispr-associated proteins and uses thereof
SG11201903454VA (en) Immunologically discernible cell surface variants for use in cell therapy
SG11201906192SA (en) Methods of treating cancer with anti-pd-1 antibodies
SG11201403106SA (en) Anti-phf-tau antibodies and their uses
SG11201808242UA (en) Methods for inhibiting angiogenesis in a subject in need thereof
SG11201909081YA (en) Anti-ilt4 antibodies and antigen-binding fragments
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201811003PA (en) Anti-pd-l1 antibodies and uses thereof
SG11201906341XA (en) Improved serum albumin binders
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201809089QA (en) Bispecific binding proteins and uses thereof
SG11201811363YA (en) Anti-zika virus antibodies and methods of use
SG11201907889YA (en) Glycan-interacting compounds and methods of use
SG11201809700YA (en) Gdf15 fusion proteins and uses thereof
SG11201900746RA (en) Engineered antibodies and other fc-domain containing molecules with enhanced agonism and effector functions
SG11201804510PA (en) Biparatopic polypeptides antagonizing wnt signaling in tumor cells
SG11201900745VA (en) Substituted thiazolo-pyridine compounds as malt1 inhibitors
SG11201807912SA (en) Vaccine against rsv
SG11201806758VA (en) Vcn enhancer compositions and methods of using the same
SG11201907769XA (en) Cd80 variant immunomodulatory proteins and uses thereof
SG11201810927QA (en) Pd-l1-specific antibodies and methods of using the same
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201810525XA (en) Anti-gitr antibodies and uses thereof
SG11201907927SA (en) Binding molecules that specifically bind to tau